Targeting ZDHHC7 may be a potential therapeutic strategy for AD, but brain region-specific palmitoylase expression differences need to be taken into account, emphasizing the importance of precisely targeted therapy (221). This evidence concerns the gene ZDHHC7 and Alzheimer disease.